Versartis, Inc. (NASDAQ:VSAR) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Monday, July 24th.
VSAR has been the topic of several other reports. Canaccord Genuity set a $28.00 target price on Versartis and gave the stock a “buy” rating in a report on Sunday, May 28th. Cantor Fitzgerald assumed coverage on Versartis in a report on Thursday, May 4th. They set an “overweight” rating and a $34.00 target price on the stock. Zacks Investment Research upgraded Versartis from a “sell” rating to a “hold” rating in a report on Thursday, June 29th. Piper Jaffray Companies boosted their target price on Versartis from $22.00 to $26.00 and gave the stock an “overweight” rating in a report on Tuesday, April 4th. Finally, ValuEngine upgraded Versartis from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $25.43.
Shares of Versartis (NASDAQ VSAR) traded up 0.61% during trading on Monday, reaching $16.60. The company had a trading volume of 148,872 shares. The company’s market capitalization is $590.59 million. The stock’s 50-day moving average price is $17.59 and its 200-day moving average price is $18.05. Versartis has a 52 week low of $9.05 and a 52 week high of $24.00.
Versartis (NASDAQ:VSAR) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.20. On average, equities analysts expect that Versartis will post ($3.25) EPS for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC raised its stake in Versartis by 6.1% in the first quarter. Perceptive Advisors LLC now owns 4,407,317 shares of the biopharmaceutical company’s stock valued at $94,096,000 after buying an additional 253,632 shares during the last quarter. Driehaus Capital Management LLC purchased a new stake in Versartis during the first quarter valued at approximately $4,117,000. Renaissance Technologies LLC raised its stake in shares of Versartis by 334.6% in the first quarter. Renaissance Technologies LLC now owns 214,700 shares of the biopharmaceutical company’s stock worth $4,584,000 after buying an additional 165,300 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Versartis by 11.9% in the second quarter. Vanguard Group Inc. now owns 1,121,401 shares of the biopharmaceutical company’s stock worth $19,569,000 after buying an additional 118,894 shares during the last quarter. Finally, ClariVest Asset Management LLC purchased a new stake in shares of Versartis during the first quarter worth about $2,480,000. 77.23% of the stock is currently owned by hedge funds and other institutional investors.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.